{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:42:20Z","timestamp":1793299340954,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018707","name":"HORIZON EUROPE Reforming and enhancing the European Research and Innovation system","doi-asserted-by":"publisher","award":["101080302"],"award-info":[{"award-number":["101080302"]}],"id":[{"id":"10.13039\/100018707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018707","name":"HORIZON EUROPE Reforming and enhancing the European Research and Innovation system","doi-asserted-by":"publisher","award":["101136299"],"award-info":[{"award-number":["101136299"]}],"id":[{"id":"10.13039\/100018707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol Exp"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to quantify hepatic vessel volumes across chronic liver disease stages and healthy controls using deep learning-based magnetic resonance imaging (MRI) analysis, and assess correlations with biomarkers for liver (dys)function and fibrosis\/portal hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed retrospectively healthy controls, non-advanced and advanced chronic liver disease (ACLD) patients using a 3D U-Net model for hepatic vessel segmentation on portal venous phase gadoxetic acid-enhanced 3-T MRI. Total (TVVR), hepatic (HVVR), and intrahepatic portal vein-to-volume ratios (PVVR) were compared between groups and correlated with: albumin-bilirubin (ALBI) and \u201cmodel for end-stage liver disease-sodium\u201d (MELD-Na) score) and fibrosis\/portal hypertension (Fibrosis-4 (FIB-4) Score, liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), platelet count (PLT), and spleen volume.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 197 subjects, aged 54.9\u2009\u00b1\u200913.8 years (mean\u2009\u00b1\u2009standard deviation), 111 males (56.3%): 35 healthy controls, 44 non-ACLD, and 118 ACLD patients. TVVR and HVVR were highest in controls (3.9; 2.1), intermediate in non-ACLD (2.8; 1.7), and lowest in ACLD patients (2.3; 1.0) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.001). PVVR was reduced in both non-ACLD and ACLD patients (both 1.2) compared to controls (1.7) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.001), but showed no difference between CLD groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.999). HVVR significantly correlated indirectly with FIB-4, ALBI, MELD-Na, LSM, and spleen volume (\u03c1 ranging from \u22120.27 to \u22120.40), and directly with PLT (\u03c1\u2009=\u20090.36). TVVR and PVVR showed similar but weaker correlations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Deep learning-based hepatic vessel volumetry demonstrated differences between healthy liver and chronic liver disease stages and shows correlations with established markers of disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance statement<\/jats:title>\n                    <jats:p>Hepatic vessel volumetry demonstrates differences between healthy liver and chronic liver disease stages, potentially serving as a non-invasive imaging biomarker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Deep learning-based vessel analysis can provide automated quantification of hepatic vascular changes across healthy liver and chronic liver disease stages.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Automated quantification of hepatic vasculature shows significantly reduced hepatic vascular volume in advanced chronic liver disease compared to non-advanced disease and healthy liver.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Decreased hepatic vascular volume, particularly in the hepatic venous system, correlates with markers of liver dysfunction, fibrosis, and portal hypertension.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s41747-025-00612-y","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T14:59:25Z","timestamp":1755010765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["MRI-derived quantification of hepatic vessel-to-volume ratios in chronic liver disease using a deep learning approach"],"prefix":"10.1186","volume":"9","author":[{"given":"Alexander","family":"Herold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sobotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bastati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Poetter-Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Simbrunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara D.","family":"Wichtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami A.","family":"Ba-Ssalamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3527-404X","authenticated-orcid":false,"given":"Ahmed","family":"Ba-Ssalamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Langs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"612_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","volume":"383","author":"EA Tsochatzis","year":"2014","unstructured":"Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet 383:1749\u20131761. https:\/\/doi.org\/10.1016\/S0140-6736(14)60121-5","journal-title":"Lancet"},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S2468-1253(23)00438-7","volume":"9","author":"S Guix\u00e9-Muntet","year":"2024","unstructured":"Guix\u00e9-Muntet S, Quesada-V\u00e1zquez S, Gracia-Sancho J (2024) Pathophysiology and therapeutic options for cirrhotic portal hypertension. Lancet Gastroenterol Hepatol 9:646\u2013663. https:\/\/doi.org\/10.1016\/S2468-1253(23)00438-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"612_CR3","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/hep4.1855","volume":"6","author":"T Reiberger","year":"2022","unstructured":"Reiberger T (2022) The value of liver and spleen stiffness for evaluation of portal hypertension in compensated cirrhosis. Hepatol Commun 6:950\u2013964. https:\/\/doi.org\/10.1002\/hep4.1855","journal-title":"Hepatol Commun"},{"key":"612_CR4","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1007\/s00261-021-03396-y","volume":"47","author":"SK Venkatesh","year":"2022","unstructured":"Venkatesh SK, Torbenson MS (2022) Liver fibrosis quantification. Abdom Radiol (NY) 47:1032\u20131052. https:\/\/doi.org\/10.1007\/s00261-021-03396-y","journal-title":"Abdom Radiol (NY)"},{"key":"612_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1148\/radiol.2019190734","volume":"294","author":"N Bastati","year":"2020","unstructured":"Bastati N, Beer L, Mandorfer M et al (2020) Does the functional liver imaging score derived from gadoxetic acid-enhanced MRI predict outcomes in chronic liver disease? Radiology 294:98\u2013107. https:\/\/doi.org\/10.1148\/radiol.2019190734","journal-title":"Radiology"},{"key":"612_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/RLI.0000000000000286","volume":"51","author":"N Bastati","year":"2016","unstructured":"Bastati N, Wibmer A, Tamandl D et al (2016) Assessment of orthotopic liver transplant graft survival on gadoxetic acid-enhanced magnetic resonance imaging using qualitative and quantitative parameters. Invest Radiol 51:728\u2013734. https:\/\/doi.org\/10.1097\/RLI.0000000000000286","journal-title":"Invest Radiol"},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jhep.2022.04.032","volume":"77","author":"N Bastati","year":"2022","unstructured":"Bastati N, Beer L, Ba-Ssalamah A et al (2022) Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. J Hepatol 77:1005\u20131013. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.032","journal-title":"J Hepatol"},{"key":"612_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.dld.2018.01.102","volume":"68","author":"A Berzigotti","year":"2018","unstructured":"Berzigotti A, Piscaglia F, Amat-Roldan I et al (2018) Non-invasive measurement of HVPG using graph analysis of dynamic contrast-enhanced ultrasound: the CLEVER study. J Hepatol 68:76\u201377. https:\/\/doi.org\/10.1016\/j.dld.2018.01.102","journal-title":"J Hepatol"},{"key":"612_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1148\/radiol.2015141941","volume":"277","author":"I Amat-Roldan","year":"2015","unstructured":"Amat-Roldan I, Berzigotti A, Gilabert R, Bosch J (2015) Assessment of hepatic vascular network connectivity with automated graph analysis of dynamic contrast-enhanced US to evaluate portal hypertension in patients with cirrhosis: a pilot study. Radiology 277:268\u2013276. https:\/\/doi.org\/10.1148\/radiol.2015141941","journal-title":"Radiology"},{"key":"612_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1148\/radiol.13121769","volume":"268","author":"JR Eisenbrey","year":"2013","unstructured":"Eisenbrey JR, Dave JK, Halldorsdottir VG et al (2013) Chronic liver disease: noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient. Radiology 268:581\u2013588. https:\/\/doi.org\/10.1148\/radiol.13121769","journal-title":"Radiology"},{"key":"612_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/s-0040-1708806","volume":"40","author":"M Mandorfer","year":"2020","unstructured":"Mandorfer M, Hern\u00e1ndez-Gea V, Garc\u00eda-Pag\u00e1n JC, Reiberger T (2020) Noninvasive diagnostics for portal hypertension: a comprehensive review. Semin Liver Dis 40:240\u2013255. https:\/\/doi.org\/10.1055\/s-0040-1708806","journal-title":"Semin Liver Dis"},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.3390\/s21062027","volume":"21","author":"M Ciecholewski","year":"2021","unstructured":"Ciecholewski M, Kassja\u0144ski M (2021) Computational methods for liver vessel segmentation in medical imaging: a review. Sensors (Basel) 21:2027. https:\/\/doi.org\/10.3390\/s21062027","journal-title":"Sensors (Basel)"},{"key":"612_CR13","doi-asserted-by":"publisher","unstructured":"\u00c7i\u00e7ek \u00d6, Abdulkadir A, Lienkamp SS, Brox T, Ronneberger O (2016) 3D U-Net: learning dense volumetric segmentation from sparse annotation. In: Ourselin S, Joskowicz L, Sabuncu M, Unal G, Wells W (eds) Medical image computing and computer-assisted intervention (MICCAI 2016). Lecture notes in computer science, vol 9901. Springer, Cham, pp 424\u2013432. https:\/\/doi.org\/10.1007\/978-3-319-46723-8_49","DOI":"10.1007\/978-3-319-46723-8_49"},{"key":"612_CR14","doi-asserted-by":"publisher","unstructured":"Thomson BR, Smit JN, Ivashchenko OV et al (2020) MR-to-US registration using multiclass segmentation of hepatic vasculature with a reduced 3D U-Net. In: Martel AL, Abolmaesumi P, Stoyanov D et al (eds) Proceedings of medical image computing and computer assisted intervention (MICCAI 2020) 23rd international conference. Springer, pp 275\u2013284. https:\/\/doi.org\/10.1007\/978-3-030-59716-0_27","DOI":"10.1007\/978-3-030-59716-0_27"},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.compbiomed.2018.08.018","volume":"101","author":"Q Huang","year":"2018","unstructured":"Huang Q, Sun J, Ding H, Wang X, Wang G (2018) Robust liver vessel extraction using 3D U-Net with variant dice loss function. Comput Biol Med 101:153\u2013162. https:\/\/doi.org\/10.1016\/j.compbiomed.2018.08.018","journal-title":"Comput Biol Med"},{"key":"612_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44736-w","volume":"13","author":"N Oh","year":"2023","unstructured":"Oh N, Kim JH, Rhu J et al (2023) Automated 3D liver segmentation from hepatobiliary phase MRI for enhanced preoperative planning. Sci Rep 13:17605. https:\/\/doi.org\/10.1038\/s41598-023-44736-w","journal-title":"Sci Rep"},{"key":"612_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.compmedimag.2024.102369","volume":"114","author":"D Sobotka","year":"2024","unstructured":"Sobotka D, Herold A, Perkonigg M et al (2024) Improving vessel segmentation with multi-task learning and auxiliary data available only during model training. Comput Med Imaging Graph 114:102369. https:\/\/doi.org\/10.1016\/j.compmedimag.2024.102369","journal-title":"Comput Med Imaging Graph"},{"key":"612_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26328-2","volume":"12","author":"L Zbinden","year":"2022","unstructured":"Zbinden L, Catucci D, Suter Y et al (2022) Convolutional neural network for automated segmentation of the liver and its vessels on non-contrast T1 vibe Dixon acquisitions. Sci Rep 12:22059. https:\/\/doi.org\/10.1038\/s41598-022-26328-2","journal-title":"Sci Rep"},{"key":"612_CR19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/jmri.21718","volume":"29","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Zhang XM, Prowda JC et al (2009) Changes in hepatic venous morphology with cirrhosis on MRI. J Magn Reson Imaging 29:1085\u20131092. https:\/\/doi.org\/10.1002\/jmri.21718","journal-title":"J Magn Reson Imaging"},{"key":"612_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/HEP.0000000000000829","volume":"80","author":"G Semmler","year":"2024","unstructured":"Semmler G, Hartl L, Mendoza YP et al (2024) Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension. Hepatology 80:887\u2013900. https:\/\/doi.org\/10.1097\/HEP.0000000000000829","journal-title":"Hepatology"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C (2022) Baveno VII\u2014renewing consensus in portal hypertension. J Hepatol 76:959\u2013974. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022","journal-title":"J Hepatol"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00508-023-02229-w","volume":"135","author":"M Mandorfer","year":"2023","unstructured":"Mandorfer M, Aigner E, Cejna M et al (2023) Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV). Wien Klin Wochenschr 135:493\u2013523. https:\/\/doi.org\/10.1007\/s00508-023-02229-w","journal-title":"Wien Klin Wochenschr"},{"key":"612_CR23","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57613","volume":"9","author":"A Wolny","year":"2020","unstructured":"Wolny A, Cerrone L, Vijayan A et al (2020) Accurate and versatile 3D segmentation of plant tissues at cellular resolution. Elife 9:e57613. https:\/\/doi.org\/10.7554\/eLife.57613","journal-title":"Elife"},{"key":"612_CR24","doi-asserted-by":"publisher","unstructured":"Kingma DP, Ba J (2014) Adam: a method for stochastic optimization. https:\/\/doi.org\/10.48550\/arXiv.1412.6980","DOI":"10.48550\/arXiv.1412.6980"},{"key":"612_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1006\/cgip.1994.1042","volume":"56","author":"TC Lee","year":"1994","unstructured":"Lee TC, Kashyap RL, Chu CN (1994) Building skeleton models via 3-D medial surface axis thinning algorithms. CVGIP Graph Model Image Process 56:462\u2013478. https:\/\/doi.org\/10.1006\/cgip.1994.1042","journal-title":"CVGIP Graph Model Image Process"},{"key":"612_CR26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI grade. J Clin Oncol 33:550\u2013558. https:\/\/doi.org\/10.1200\/JCO.2014.57.9151","journal-title":"J Clin Oncol"},{"key":"612_CR27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa0801209","volume":"359","author":"WR Kim","year":"2008","unstructured":"Kim WR, Biggins SW, Kremers WK et al (2008) Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 359:1018\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa0801209","journal-title":"N Engl J Med"},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K et al (2009) Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7:1104\u20131112. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.033","journal-title":"Clin Gastroenterol Hepatol"},{"key":"612_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43:1317\u20131325. https:\/\/doi.org\/10.1002\/hep.21178","journal-title":"Hepatology"},{"key":"612_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4254\/wjh.v6.i1.41","volume":"6","author":"YM Fouad","year":"2014","unstructured":"Fouad YM, Yehia R (2014) Hepato-cardiac disorders. World J Hepatol 6:41\u201354. https:\/\/doi.org\/10.4254\/wjh.v6.i1.41","journal-title":"World J Hepatol"},{"key":"612_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.5152\/dir.2020.19673","volume":"26","author":"A Morales","year":"2020","unstructured":"Morales A, Hirsch M, Schneider D, Gonz\u00e1lez D (2020) Congestive hepatopathy: the role of the radiologist in the diagnosis. Diagn Interv Radiol 26:541\u2013545. https:\/\/doi.org\/10.5152\/dir.2020.19673","journal-title":"Diagn Interv Radiol"},{"key":"612_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s13244-014-0336-2","volume":"5","author":"JF Gerstenmaier","year":"2014","unstructured":"Gerstenmaier JF, Gibson RN (2014) Ultrasound in chronic liver disease. Insights Imaging 5:441\u2013455. https:\/\/doi.org\/10.1007\/s13244-014-0336-2","journal-title":"Insights Imaging"},{"key":"612_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/IJGM.S342087","volume":"15","author":"T Ayele","year":"2022","unstructured":"Ayele T, Gebremickael A, Alemu Gebremichael M et al (2022) Ultrasonographic determination of portal vein diameter among adults with and without chronic liver disease at selected referral hospitals in Southern Ethiopia. Int J Gen Med 15:45\u201352. https:\/\/doi.org\/10.2147\/IJGM.S342087","journal-title":"Int J Gen Med"},{"key":"612_CR34","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.15557\/jou.2023.0011","volume":"23","author":"OD Ogholoh","year":"2023","unstructured":"Ogholoh OD, Zaccheus AO, Ikubor JE, Nwafor NN, Idowu BM, Ogholoh GI (2023) Portal vein congestion index in patients with and without chronic liver disease. J Ultrason 23:e53\u2013e60. https:\/\/doi.org\/10.15557\/jou.2023.0011","journal-title":"J Ultrason"},{"key":"612_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1515\/arsm-2016-0022","volume":"22","author":"CA Achim","year":"2016","unstructured":"Achim CA, Bordei P, Dumitru E (2016) The role of ultrasonography in the evaluation of portal hemodynamics in healthy adults and pathologic conditions. ARS Med Tomitana 22:128\u2013134. https:\/\/doi.org\/10.1515\/arsm-2016-0022","journal-title":"ARS Med Tomitana"},{"key":"612_CR36","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1002\/hep.31836","volume":"74","author":"RK Jagdish","year":"2021","unstructured":"Jagdish RK, Maras JS, Sarin SK (2021) Albumin in advanced liver diseases: the good and bad of a drug! Hepatology 74:2848\u20132862. https:\/\/doi.org\/10.1002\/hep.31836","journal-title":"Hepatology"},{"key":"612_CR37","first-page":"138","volume":"52","author":"A Ohkubo","year":"1994","unstructured":"Ohkubo A (1994) Bilirubin metabolism in liver cirrhosis. Nihon Rinsho 52:138\u2013144","journal-title":"Nihon Rinsho"},{"key":"612_CR38","doi-asserted-by":"publisher","first-page":"e7142","DOI":"10.1097\/MD.0000000000007142","volume":"96","author":"B Chen","year":"2017","unstructured":"Chen B, Lin S (2017) Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore) 96:e7142. https:\/\/doi.org\/10.1097\/MD.0000000000007142","journal-title":"Medicine (Baltimore)"},{"key":"612_CR39","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.3748\/wjg.v28.i30.4061","volume":"28","author":"P Gallo","year":"2022","unstructured":"Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U (2022) Thrombocytopenia in chronic liver disease: physiopathology and new therapeutic strategies before invasive procedures. World J Gastroenterol 28:4061\u20134074. https:\/\/doi.org\/10.3748\/wjg.v28.i30.4061","journal-title":"World J Gastroenterol"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1172\/JCI105380","volume":"45","author":"RH Aster","year":"1966","unstructured":"Aster RH (1966) Pooling of platelets in the spleen: role in the pathogenesis of \u201chypersplenic\u201d thrombocytopenia. J Clin Invest 45:645\u2013657. https:\/\/doi.org\/10.1172\/JCI105380","journal-title":"J Clin Invest"},{"key":"612_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1160\/TH08-01-0006","volume":"99","author":"M Uemura","year":"2008","unstructured":"Uemura M, Fujimura Y, Matsumoto M et al (2008) Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 99:1019\u20131029. https:\/\/doi.org\/10.1160\/TH08-01-0006","journal-title":"Thromb Haemost"},{"key":"612_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/HMER.S74612","volume":"8","author":"O Mitchell","year":"2016","unstructured":"Mitchell O, Feldman DM, Diakow M, Sigal SH (2016) The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med 8:39\u201350. https:\/\/doi.org\/10.2147\/HMER.S74612","journal-title":"Hepat Med"},{"key":"612_CR43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00508-012-0190-5","volume":"124","author":"T Reiberger","year":"2012","unstructured":"Reiberger T, Ferlitsch A, Payer BA et al (2012) Noninvasive screening for liver fibrosis and portal hypertension by transient elastography\u2014a large single center experience. Wien Klin Wochenschr 124:395\u2013402. https:\/\/doi.org\/10.1007\/s00508-012-0190-5","journal-title":"Wien Klin Wochenschr"}],"container-title":["European Radiology Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-025-00612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41747-025-00612-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-025-00612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T14:59:26Z","timestamp":1755010766000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurradiolexp.springeropen.com\/articles\/10.1186\/s41747-025-00612-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1186\/s41747-025-00612-y","relation":{},"ISSN":["2509-9280"],"issn-type":[{"value":"2509-9280","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"8 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board approval was obtained (IRB-No. 1521\/2015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB: honoraria for consulting from Bayer, speaker fees from Bayer and Siemens. TR received grant support from AbbVie, Boehringer Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore & Associates; speaking honoraria from AbbVie, Gilead, Intercept, Roche, MSD, W. L. Gore & Associates; consulting\/advisory board fees from AbbVie, Bayer, Boehringer Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from AbbVie, Boehringer Ingelheim, Gilead and Roche. MM received grants from Echosens, served as a speaker and\/or consultant and\/or advisory board member for AbbVie, Collective Acumen, Echosens, Gilead, Ipsen, Takeda, and W. L. Gore & Associates, and received travel support from AbbVie and Gilead. BS received travel support from AbbVie, Gilead, and Falk. GS received travel support from Amgen. MT received grant support from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx, honoraria for consulting from AbbVie, Albireo, Agomab, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Jannsen, Mirum, MSD, Novartis, Phenex, Pliant, Rectify, Regulus, Siemens and Shire, speaker fees from Albireo, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Gilead, Ipsen, Intercept, MSD and Madrigal, as well as travel support from AbbVie, Falk, Gilead, Jannsen and Intercept. He is also co-inventor (service inventions as an employee) of patents on the medical use of 24-norursodeoxycholic acid filed and owned by the Medical University of Graz. BW has given scientific presentations for Philips GmbH for which monetary compensation was received. GL reports a relationship with Siemens Healthineers, Boehringer Ingelheim GmbH and Roche that includes speaking and lecture fees, and a relationship with Contextflow GmbH that includes equity or stocks. GL and DS received funding from Novartis Pharmaceuticals Corporation. AH, SPL, NB, LB, SB, MW: nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}